MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

Search

ENANTA PHARMACEUTICALS INC

Open

SectorHealthcare

4.68 5.88

Overview

Share price change

24h

Current

Min

4.26

Max

4.8

Key metrics

By Trading Economics

Income

94M

-22M

Sales

-51M

17M

EPS

-1.05

Profit margin

-131.435

Employees

131

EBITDA

-20M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+204.44% upside

Dividends

By Dow Jones

Next Earnings

5 maj 2025

Market Stats

By TradingEconomics

Market Cap

-234M

122M

Previous open

-1.2

Previous close

4.68

News Sentiment

By Acuity

50%

50%

173 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

ENANTA PHARMACEUTICALS INC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 kwi 2025, 23:56 UTC

Top News

Australian Consumer Confidence Firms Despite Market Falls

7 kwi 2025, 23:45 UTC

Hot Stocks

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

7 kwi 2025, 21:36 UTC

Major Market Movers

Medicare Insurer Shares Rise on Plans for Higher Payment Rates

7 kwi 2025, 21:11 UTC

Major Market Movers

Broadcom Authorizes $10 Billion Share Repurchase Program

7 kwi 2025, 23:48 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

7 kwi 2025, 23:47 UTC

Market Talk

Gold Edges Lower Amid More Cautious Near-Term Outlook -- Market Talk

7 kwi 2025, 23:34 UTC

Top News

Apple Users Rush to Upgrade iPhones Ahead of Potential Tariffs-Related Price Hikes -- WSJ

7 kwi 2025, 22:18 UTC

Top News

Health Insurer Stocks Jump After Medicare Boosts Payment Rates -- Barrons.com

7 kwi 2025, 21:43 UTC

Market Talk

Oil Producers Choosing Returns Over Growth In Tariffs Fallout -- Market Talk

7 kwi 2025, 21:37 UTC

Market Talk

Canada Faces Financial Crisis-Like Symptoms That Rate Cuts Won't Cure -- Market Talk

7 kwi 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Infineon: All-Cash Transaction to Be Financed From Existing Liquidity and Additional Debt >IFX.FF

7 kwi 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Infineon: Transaction Combines Infineon's Portfolio for Automotive Microcontrollers With Automotive Ethernet Business of Marvell, Accelerating Infineon's System Capabilities for Software-Defined Vehicles >IFX.FF

7 kwi 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Infineon: Business Expected to Generate Rev of $225M-$250M in Calendar Yr 2025 With Gross Margin of Around 60% >IFX.FF

7 kwi 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Infineon: Enters Agreement for Acquisition of Marvell Technology's Automotive Ethernet Business for US$2.5 B >IFX.FF

7 kwi 2025, 21:31 UTC

Top News

Apple Plans to Source More iPhones From India as Potential Tariff Fix -- Update

7 kwi 2025, 21:29 UTC

Top News

PNC Names Former BlackRock Star Mark Wiedman as President -- WSJ

7 kwi 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Infineon Further Strengthens Its Number One Position In Automotive Microcontrollers And Boosts Systems Capabilities For Software-defined Vehicles With Acquisition Of Marvell's Automotive Ethernet Business >IFNNY MRVL

7 kwi 2025, 21:21 UTC

Top News

Defense Stocks Can't Escape the Trade War. Expect to Hear This Term. -- Barrons.com

7 kwi 2025, 21:18 UTC

Top News
Earnings

Levi Strauss Trying to Mitigate Tariff Impact on Consumer; Company Grows Revenue -- Update

7 kwi 2025, 21:17 UTC

Earnings

Levi Sees U.S. Consumer 'Generally Resilient,' CFO Says

7 kwi 2025, 21:17 UTC

Earnings

Levi Looking at Cost-Related Opportunities, Pricing Changes as Part of Response, CFO Says

7 kwi 2025, 21:16 UTC

Earnings

Levi Strauss Sets Up Task Force to Understand Implications of Trump's Tariffs, CFO Singh Says

7 kwi 2025, 21:16 UTC

Top News

What to Know About Trump's Latest Tariffs -- 3rd Update

7 kwi 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Marvell to Sell In-Vehicle Network Portfolio for $2.5B

7 kwi 2025, 21:14 UTC

Top News

PNC Taps Ex-BlackRock Star Mark Wiedman as President -- WSJ

7 kwi 2025, 21:06 UTC

Top News
Acquisitions, Mergers, Takeovers

Trump Orders New Review of Nippon-U.S. Steel Merger -- 3rd Update

7 kwi 2025, 21:03 UTC

Top News

Even Google Could Feel the Sting of a Trade War -- Barrons.com

7 kwi 2025, 20:59 UTC

Top News

U.S. Stock Meltdown Gives Way to Global Rout -- WSJ

7 kwi 2025, 20:56 UTC

Major Market Movers

Broadcom Authorizes $10B Share Repurchase Program

7 kwi 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

ENANTA PHARMACEUTICALS INC Forecast

Price Target

By TipRanks

204.44% upside

12 Months Forecast

Average 14.4 USD  204.44%

High 21 USD

Low 5 USD

Based on 5 Wall Street analysts offering 12 month price targets forENANTA PHARMACEUTICALS INC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

3

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

4.5201 / 5.87Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

173 / 386 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.